The Development of Dyslipidemia in Chronic Kidney Disease and Associated Cardiovascular Damage, and the Protective Effects of Curcuminoids.
Zeltzin Alejandra Ceja-GaliciaAna Karina Aranda-RiveraIsabel Amador-MartínezOmar Emiliano Aparicio-TrejoEdilia TapiaJoyce TrujilloVictoria Ramirez-GonzalezPedraza-Chaverri JoséPublished in: Foods (Basel, Switzerland) (2023)
Chronic kidney disease (CKD) is a health problem that is constantly growing. This disease presents a diverse symptomatology that implies complex therapeutic management. One of its characteristic symptoms is dyslipidemia, which becomes a risk factor for developing cardiovascular diseases and increases the mortality of CKD patients. Various drugs, particularly those used for dyslipidemia, consumed in the course of CKD lead to side effects that delay the patient's recovery. Therefore, it is necessary to implement new therapies with natural compounds, such as curcuminoids (derived from the Curcuma longa plant), which can cushion the damage caused by the excessive use of medications. This manuscript aims to review the current evidence on the use of curcuminoids on dyslipidemia in CKD and CKD-induced cardiovascular disease (CVD). We first described oxidative stress, inflammation, fibrosis, and metabolic reprogramming as factors that induce dyslipidemia in CKD and their association with CVD development. We proposed the potential use of curcuminoids in CKD and their utilization in clinics to treat CKD-dyslipidemia.
Keyphrases
- chronic kidney disease
- end stage renal disease
- oxidative stress
- cardiovascular disease
- diabetic rats
- public health
- primary care
- type diabetes
- cardiovascular events
- mental health
- metabolic syndrome
- depressive symptoms
- weight gain
- induced apoptosis
- climate change
- peritoneal dialysis
- high glucose
- health information
- patient reported
- endoplasmic reticulum stress